Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors

We obtained antibodies and reagents from various sources. Human plasma FN was purified as a by-product of Factor VIII. Poly-L-lysine (PLL) and bovine serum albumin (BSA; 98%) were purchased from Sigma Chemical Co (St. Louis, MO).

Blocking antibodies against the integrins α4 (P4C2), α5 (P1D6), β1 (P4C10), and α2 (P1E6) were purchased from Gibco-BRL (Grand Island, NY). The activating anti–β1-antibody, 8A2, was a kind gift from Dr Kovach, University of Washington (Seattle, WA).35 Antibodies against CD34 and CD62L were purchased from Becton Dickinson (Mountain View, CA), and mouse immunoglobulin G (IgG) was purchased from Sigma. FITC-conjugated goat antimouse antibody was obtained from Biosource International, Camarillo, CA.

For the flow-cytometric assessment of the cell cycle, unconjugated antibodies against p21^CIP1, p27^KIP1, p16^INK4A, and cyclin-E and fluorescein (FITC)–conjugated antibodies against cyclin-A and cyclin-D_{1 + 2 + 3} were obtained from Pharmingen Inc (San Diego, CA). FITC-coupled anti-PCNA antibodies were obtained from DAKO Inc. Secondary goat antimouse FITC antibodies as well as isotype-control antibodies were also purchased from Pharmingen Inc.

For use in immunoprecipitation and Western blot, antibodies against p21^CIP1, p27^KIP1, Cyclin-E, Cdk2, and β-actin were obtained from Pharmingen Inc. Secondary goat antimouse horseradish peroxydase (HRP)–conjugated antibodies were obtained from Pharmingen Inc.

The following cytokines were purchased from R&D Systems (Minneapolis, MN): IL3, IL6, leukemia inhibitory factor (LIF), and macrophage-inflammatory protein (MIP)–1α. SCF was a kind gift from Amgen Inc (Thousand Oaks, CA); fetal liver tyrosine kinase-3 ligand (Flt3-L) was a kind gift from Immunex Inc (Seattle, WA). GM-CSF was purchased from Immunex, and erythropoietin and G-CSF were purchased from Amgen.

We obtained 50 mL of heparinized BM from normal donors under steady-state conditions. To obtain mobilized peripheral blood (PB) progenitors, we selected normal donors using the standard criteria of the American Association of Blood Banks for blood donors. The donors received a daily dose of 10 μg/kg/d G-CSF subcutaneous for 5 days. On day 6 donors underwent an apheresis procedure, as previously described.36 All donors signed an informed consent according to the guidelines from the Committee for the Protection of Human Subjects at the University of Minnesota.

Steady-state BM- and G-CSF–mobilized PB mononuclear cells were separated by Ficoll Hypaque centrifugation (specific gravity, 1077) (Sigma). CD34⁺ cells were selected either by 2 passages over the MACS CD34 Isolation Kit (Miltenyi Biotec, Sunnyvale, CA) or by sequential selection with the Ceprate SC device for clinical scale stem cell concentration (CellPro, Bhotell, WA) followed by the MACS CD34 Isolation Kit.36 CD34⁺ populations were more than 95% pure.

As a low-dose cytokine, serum-free medium, we used Iscove's Modified Dulbecco's Medium (IMDM, Gibco) containing 20 mg/mL BSA, 10 μg/mL insulin (Sigma), 200 μg/mL transferrin (Sigma), 10^-4mol/L 2-mercapto-ethanol (Bio-Rad, Hercules, CA), 100 U/mL penicillin and 100 U/mL streptomycin (Gibco), and the following cytokines37: 200 pg/mL GM-CSF, 1000 pg/mL G-CSF, 200 pg/mL SCF, 50 pg/mL LIF, 200 pg/mL MIP-1α, and 1000 pg/mL IL-6.

Integrins were engaged in two ways. One way was to cause them to adhere to FN. In this method, CD34⁺ cells suspended in serum-free IMDM with or without cytokines were plated onto wells coated with 100 μg/mL FN or 10 μg/mL PLL in a humidified atmosphere at 37°C.3,5,7 Adherent and nonadherent cells were collected after 2 hours to assess adhesion and at 12 to 16 hours to assess cell cycle status as described.3,5 7 

Integrins were also engaged in solution. In this method, CD34⁺ cells were incubated in IMDM, with or without cytokines and with adhesion-blocking antibodies against the β1-, α2-, α4- and α5-integrins, CD62L (all at 10 μg/mL), or mouse IgG control for 30 minutes at 37°C.7 Cells were washed and incubated with goat antimouse antibody (1:500 dilution) for 8 to 12 hours at 37°C in a humidified atmosphere.

We assessed cell adhesion in two ways. In the ⁵¹Cr labeled adhesion assay, CD34⁺ cells were labeled with 0.1 mCi⁵¹Cr (specific activity 734.5 mCi/mg; NEN, Boston, MA) for 1 hour at 37°C and washed twice. ⁵¹Cr-labeled CD34⁺ cells suspended in IMDM with or without cytokines were plated in ligand-coated dishes for 2 hours. Nonadherent cells were collected. Adherent cells were lysed with triton-X-100 (Sigma), wells were harvested, and ⁵¹Cr emission was counted with the use of a Gamma 4000 Counting System (Beckman Instruments, Irvine, CA).37 The percentage of adhesion was calculated as follows: % = (cpm emission in adherent cells − cpm background) / (cpm emission in all cells − cpm background) × 100.

We also assessed cells for adherence to CFC. In this method, CD34⁺ cells incubated in IMDM with or without cytokines were plated in ligand-coated dishes for 2 hours. Nonadherent cells were collected in 3 washes, as described.3,5 Adherent cells were collected after trypsinization for 7 minutes. The percentage of adhesion of CFC was determined by replating adherent and nonadherent CD34⁺ cells in methylcellulose assay and enumerating CFC in the adherent and nonadherent portion.3 5The percentage of adhesion was determined as follows: % adhesion = (CFC in adherent cells) / (CFC in adherent + nonadherent portion) × 100.

We performed various procedures to assess cell cycle and cell cycle regulatory elements. A flow-cytometric evaluation of cell cycle38 was performed in the following way: CD34⁺ cells incubated in IMDM with or without cytokines were plated in ligand-coated dishes for 12 to 16 hours. Nonadherent cells were collected in 3 washes, as described.3,5 Adherent cells were collected after trypsinization for 7 minutes. We have previously shown that trypsin does not affect assessment of cell cycle.5 Freshly collected CD34⁺ cells or adherent or nonadherent CD34⁺ cells recovered after 12 hours of adhesion to BSA, PLL, or FN were fixed in 75% ethanol and stained with propidium iodide (50 μg/mL propidium iodide Σ, and 10 μg/mL RNase Σ in phosphate buffer saline (PBS) [Gibco]).39 Cells were analyzed with a FACS-Calibur flow cytometer (Becton Dickinson). Cell cycle phase distribution was calculated with the use of ModFit LT software (Verity Software House Inc). In some experiments, CD34⁺ cells selected from G-CSF–mobilized PB were cocultured with BSA, FN, or PLL in the presence of low-dose cytokines with or without IL3 or SCF. After 60 hours, cell cycle status was evaluated by fluorescence-activated cell sorter (FACS).

Flow cytometric evaluation of cell cycle proteins was performed as follows: CD34⁺ cells recovered in the adherent and nonadherent portion of adhesion assays were fixed in 75% ethanol, then incubated overnight at −20°C.40 For assessment of cyclin-D, cells were fixed in 1% formaldehyde (Sigma) for 15 minutes before fixation in ethanol. Cells were washed and permeabilized with 0.15% Triton X-100 (Sigma) for 5 minutes, washed, and then incubated with antibodies directed at PCNA, cyclin-D_{1 + 2 + 3}, cyclin-E, cyclin-A, p16^INK4A, p21^CIP1, and p27^KIP1 or with isotype control antibody at room temperature for 30 minutes. When unconjugated antibodies were used, cells were washed and incubated with FITC-conjugated goat antimouse Ig for 30 minutes in the dark. Cells were washed and resuspended in 50 μg/mL propidium iodide. Cells were analyzed with a FACS-Calibur flow cytometer with the use of Cell Quest and ModFit LT software. In some experiments, CD34+ cells selected from G-CSF–mobilized PB, which had not been cultured with low doses of cytokines to induce cell proliferation, were cocultured with FN or PLL in the presence of low-dose cytokines with or without IL3 or SCF. After 60 hours, levels of p27^KIP1 were assessed by FACS and Western blot.

A thymidine suicide assay was performed as follows: CFC proliferation was assessed in ³H-thymidine suicide assays as described.5 7 (1) Adherent and nonadherent CD34⁺ cells recovered after 12-hour adhesion to BSA, PLL, or FN or (2) CD34⁺ cells incubated with blocking or nonblocking anti-integrin antibodies or control antibodies for 12 hours were incubated at 37°C in serum-free IMDM for 30 minutes with or without 5 mCi ³H thymidine (specific activity, 6.7 Ci/mmol, NEN), washed with excess cold thymidine (500 mg/mL Σ in IMDM plus 20% FCS), and plated in methylcellulose assays. The percentage of CFC in S phase was calculated as follows: % CFC in S-phase = [(number of CFC without³H-thymidine − Number of CFC with³H-thymidine) × 100] / [number of CFC without ³H-thymidine].

In Western blotting and immunoprecipitation,39 cells recovered in the adherent and nonadherent portion of adhesion assay were lysed in NP-40 lysis buffer (50 mmol/L Tris HCl, pH 7.4, 250 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic acid, 1% NP-40, 1 mmol/L phenylmethyl–sulfonyl fluoride (PMSF), 10 μg/mL aprotinin, 10 μg/mL leupeptin, 50 mmol/L NaFl, 0.1 mmol/L Na₃VO₄, all from Sigma), and lysates were recovered by centrifugation. Total protein from each sample to be used in Western blots or immunoprecipitations was normalized with the use of the Bradford assay.

In Western blotting, protein lysates from more than 2 × 10⁶ adherent, nonadherent, or unmanipulated cells were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose with the use of a Semidry Transfer Apparatus (Bio-Rad). Immunoblots were blocked in freshly prepared TBS (Pierce, Rockford, IL) containing 5% nonfat dry milk. Blots were incubated with 1 ng/mL primary antibody in blocking buffer for 2 hours at room temperature. After 4 washes in TBST (TBS supplemented with 0.05% Tween 20), blots were incubated for 1 hour with a goat antimouse HRP-conjugated antibody (1:10 000 dilution). Bands were visualized with the use of an ECL detection system (E.I. du Pont de Nemours & Co, Boston, MA). Quantitative differences in protein levels in different conditions were evaluated by scanning images with a GS-700 Imaging Densitometer (Bio-Rad); the images were then quantitated with the use of Molecular Analyst software (Bio-Rad).

In immunoprecipitation, protein lysates were precleared with 50 μL protein-G-agarose (Boehringer Mannheim, Indianapolis, IN) for at least 3 hours on a rocking platform, and nonbound material was recovered by centrifugation. We added 1 μg/mL anti–cyclin-E or anti-cdk2 antibody, and the mixture was gently rocked for at least 2 hours at 4°C. Soluble immune complexes were incubated with 100 μL protein-G-agarose beads for 3 hours and bead/protein complexes recovered by centrifugation. Beads were washed 3 times for 20 minutes with lysis buffer, and bound material was eluted by boiling in 1% SDS. The immune complexes were resolved by SDS-PAGE and blots probed as described above. Differences were evaluated with the use of a GS-700 Imaging Densitometer (Bio-Rad), and the images were then quantitated with the use of Molecular Analyst software.

A histone H1 kinase assay was performed as follows: Cdk2-associated kinase activity was assayed in cdk2- or cyclin-E–immune complexes. Cell lysates were prepared as described above, and cyclin-E or cdk2 was immunoprecipitated from similar quantities of protein. Bead/protein complexes were washed 3 times with lysis buffer and twice with kinase buffer (50 mmol/L Tris-HCl [pH 7.5], 10 mmol/L MgCl₂, and 1 mmol/L dithiothreitol). Then, 5 μg histone H1 (Boehringer Mannheim), 1 μM ATP, and 10 μCi [r-³²P] were added to the kinase buffer for 30 minutes at 30°C. The reaction was stopped by adding Laemmli sample buffer and boiling for 3 minutes. Reaction products were resolved by SDS-PAGE. The gel was dried and exposed to X-ray film. Differences were evaluated by scanning images with the use of a GS-700 Imaging Densitometer (Bio-Rad); the images were then quantitated with the use of Molecular Analyst software.

Results of experimental points obtained from multiple experiments were reported as the mean ± SEM. Significance levels were determined by a 2-sided Student t test.

We have shown that 25% to 30% of CFC present in normal, steady-state BM are in S phase,5,7 and that entry in S phase is inhibited following coculture with FN5 or when β1-integrins are engaged directly by adhesion-blocking antibodies.7 We now show that 95% to 99% of mobilized PB CFC and CD34⁺ are in G₀/G₁(n = 5); this is consistent with other published reports.41,42 Culture for 48 hours with cytokines at concentrations found in the BM microenvironment (200 pg/mL GM-CSF, 1000 pg/mL G-CSF, 200 pg/mL SCF, 50 pg/mL LIF, 200 pg/mL MIP-1α, and 1000 pg/mL IL-6)37 caused 23 ± 3% of mobilized PB CD34⁺ cells (n = 4) and 29 ± 4% of mobilized PB CFC (n = 14) to enter S phase. We then evaluated whether G-CSF–mobilized PB CD34⁺ cells undergo similar adhesion-mediated proliferation inhibition as CD34⁺ cells in steady-state BM.

In a first set of experiments, CD34⁺ cells were induced to proliferate by culturing in low doses of cytokines for 48 to 72 hours. Cultured PB CD34⁺ cells were then plated for 12 hours in FN-, BSA-, or PLL-coated wells. We have previously shown that although mobilized PB CD34⁺ cells express fewer α4β1 integrins, and therefore interact less well with fibronectin, expression of α4β1 increases to normal levels after 24-to-48-hour culture with cytokines ex vivo. Coculture with FN, but not with BSA or PLL, resulted in a significant decrease in the portion of CFC (8.5 ± 3%) (Figure 1A) and CD34⁺ cells (11.5% ± 2%) (Figure 1B) adherent to FN in S phase. Several observations indicate that this is not due to selective adhesion of G₀/G₁ cells: (1) The percentage of CFC in S phase in the adherent and the nonadherent populations combined was significantly lower for cells cocultured with FN than for cells cultured with either BSA or PLL; (2) Incubation of CD34⁺ cells with the β1-integrin–activating antibody 8A2 increased CD34⁺ cell adhesion (without 8A2, 10 ± 1%; with 8A2, 40 ± 1.4%). The cell cycle status of CD34⁺ cells present in the FN-adherent and FN-nonadherent portions of assays performed in the presence or absence of 8A2 was, however, equivalent (FN-adherent CD34⁺ cells: without 8A2 = 11 ± 3% S-phase, n = 3; with 8A2 = 11.5 ± 1.6% S phase, n = 9; FN-nonadherent CD34⁺ cells: without 8A2 = 21 ± 4% S phase, n = 3; with 8A2 = 22.5 ± 2% S phase, n = 9); (3) Engagement of β1-integrins (4 ± 2.4% S phase), α5-integrins (10 ± 5.8% S phase), and α4-integrins (10.5 ± 6.8% S phase), but not the α2-integrin or CD62L, with adhesion-blocking antibodies and cross-linking with a secondary goat antimouse antibody decreased the portion of CFC in S phase (Figure2). Although the portion of CFC exposed to anti–α4-b anti–α5-b or anti–β1-integrin antibodies and FN-adherent CFC that were in S phase was similar, the percentage of CFC cultured in FN-coated wells in S phase (ie, in FN-adherent plus FN-nonadherent portions) was higher than in antibody-exposed CFC. This is consistent with the fact that most CD34⁺ cells express β1-integrins, and antibody-mediated engagement of β1 therefore suppresses S-phase entry in the majority of cells, whereas only 10% to 15% adhere to FN in the absence of 8A2. Adhesion via β1-integrins therefore inhibits cell cycle progression in the adherent portion only. Thus, these studies are consistent with the concept that block in cell cycle progression in FN-adherent cells is caused by engagement of integrins by FN and not by selective adhesion of G₀/G₁ cells.

To confirm this further, we tested the hypothesis that culture of freshly isolated PB CD34⁺ cells, which are in G₀/G₁, on FN rather than on BSA- or PLL-containing wells would delay entry of CD34⁺ cells into S phase (Figure 3). Freshly sorted CD34⁺ cells (n = 2) suspended in low-dose cytokine-containing serum-free medium were cultured in wells coated with FN or PLL. After 24, 48, and 60 hours, adherent and nonadherent cells were collected, and cell cycle status was assessed by FACS. On day 0, 0.9% and 1% of CD34⁺ cells were in S phase. For PLL-adherent cells, this increased to 5% and 3% after 24 hours, to 17% and 12% after 48 hours, and to 17% and 16% after 60 hours. For cells in the FN-nonadherent CD34⁺ cell portion, 6% and 4% were in S phase after 24 hours, 17% and 13% after 48 hours, and 18% and 16% after 60 hours. In contrast, for CD34⁺ cells present in the FN-adherent portion, only 3% and 2% were in S phase after 24 hours, 7% and 4% after 48 hours, and 10% and 4% after 60 hours. This confirms that contact with FN prevents S-phase entry.

We next examined the effect of adhesion to FN on cell cycle protein expression and activity. CD34⁺ cells were plated for 48 to 72 hours in low-dose cytokine-containing medium to induce entry of cells into S phase. Cells were then plated in dishes coated with FN or PLL for 12 to 16 hours, and adherent and nonadherent cells were collected separately, permeabilized, and stained with antibodies directed at cell cycle–associated proteins. Since no significant differences were seen in the cell cycle status of cells assayed in the presence (FN-adherent: 11.4 ± 3.1% S phase; FN-nonadherent: 26.7 ± 4.9% S phase, n = 3) or absence of low-dose cytokines (FN-adherent: 11.5 ± 2% S phase; FN-nonadherent: 22.5 ± 2.3% S phase, n = 9), or in the presence or absence of the activating antibody 8A2 (see above), results from assays with or without 8A2 or with or without low-dose cytokines during the adhesion assay were pooled.

Cyclin-E protein levels were lower in FN-adherent compared with FN-nonadherent cells, and FN-adherent cells had elevated levels of p27^KIP1 compared with FN-nonadherent cells (Figure4, representative example of 5 individual experiments). FN-adherent cells contained slightly less cyclin-A than FN-nonadherent cells, and levels of PCNA, cyclin-D_{1 + 2 + 3}, p16^INK4A, and p21^CIP1 were similar in FN-adherent and FN-nonadherent cells (not shown). These results were confirmed by immunoprecipitation and Western blot. All blots were analyzed by densitometry to obtain quantitative results. Levels of p27^KIP1 were 1.99 ± 0.1-fold higher (P < .01) in FN-adherent compared with FN-nonadherent cells (Figure5, representative experiment of 3 individual experiments). Levels of cyclin-E were 4.4 ± 0.9-fold lower in FN-adherent compared with FN-nonadherent cells (Figure 5). We also immunoprecipitated cdk2 from FN-adherent and FN-nonadherent cells. Immunoprecipitates were then evaluated for the amount of cdk2 present and the activity of the kinase. In FN-adherent cells, cdk2 activity was 3.46 ± 0.16 lower than in FN-nonadherent cells (Figure5). However, the total cdk2-protein level was not significantly different between FN-adherent and FN-nonadherent cells (Figure 5). Further, the amount of cdk2 that coimmunoprecipitated with cyclin-E was 3.8 ± 0.25-fold lower in FN-adherent than FN-nonadherent cells (not shown). No differences between cells that were adherent or nonadherent to PLL were seen in PCNA, cyclin-D_{1 + 2 + 3}, cyclin-E, cyclin-A, cdk2, p16^INK4A, p21^CIP1, and p27^KIP1 protein levels and in cdk2-activity (Figures 4, 5, and not shown).

When freshly isolated CD34⁺ cells were cultured for 60 hours on PLL- or FN-coated dishes in the presence of low doses of cytokines, similar results were seen: p27^KIP1 levels were 1.5-fold higher in the FN-adherent portion compared with FN-nonadherent portion, and 1.8-fold and 2.3-fold compared with PLL-adherent and PLL-nonadherent portions, respectively. Interestingly, the level of p27^KIP1 was 2.13-fold higher in CD34⁺ cells cultured for 60 hours in FN-coated wells in the presence of low doses of cytokines compared with freshly isolated and uncultured CD34⁺ cells, even though both populations contained only a small portion of cells in S phase. Thus, contact with FN, rather than G₀/G₁ state of the cell, is associated with increased levels of p27^KIP1(Figure 3).

We next examined if supraphysiological concentrations of cytokines known to stimulate progenitor growth would affect integrin-mediated functions. Cells were cultured for 48 to 72 hours in low-dose cytokine-containing medium to induce S-phase entry. Cells were then resuspended in serum-free medium either without cytokines or with 10 ng/mL IL3, GM-CSF, SCF, or Flt-3L. The portion of CD34⁺ cells or CFC that adhered to FN was similar when adhesion assays were done in the absence or presence of any of the following: IL3, GM-CSF, SCF, or Flt-3L (Table1). In contrast to CFC cultured in contact with FN in the absence of cytokines, contact with FN in the presence of 10 ng/mL IL3, GM-CSF, SCF, or Flt-3L prevented inhibition of G₁/S–phase progression of CFC, and contact with FN in the presence of IL3 or SCF also prevented the G₀/G₁ blockade in CD34⁺cells (Table 2).

We next analyzed the expression level and activity of cell cycle proteins in FN-adherent or FN-nonadherent cells in cultures supplemented with IL3 or SCF (n = 3). To increase the portion of FN-adherent cells, we added the activating anti–β1-integrin antibody 8A2. Except for an increase in the portion of adherent cells, no differences were seen in the proliferative status of FN-adherent and FN-nonadherent cells or in the levels of cell cycle–associated proteins in the presence or absence of 8A2 (not shown). Levels of cyclin-E were higher in CD34⁺ cells adherent to FN in the presence of either IL3 (Figure 6) or SCF (data not shown) compared with CD34⁺ cells adherent to FN in the absence of cytokines. In contrast to cytokine-free assays, p27^KIP1levels were not elevated in CD34⁺ cells adherent to FN in the presence of IL3 (Figure 6) or SCF (data not shown). Levels of the other cell cycle proteins, including PCNA, cyclin-D_{1 + 2 + 3}, p21^CIP1, and p16^INK4A, were similar in the presence or absence of IL3 or SCF (not shown). Immunoprecipitation and Western blot and kinase assays (n = 3) confirmed that IL3 prevents the accumulation of p27^KIP1 and allows activation of cdk2, even when CD34⁺ cells were adherent to FN (Figure7).

We still do not know which signals are responsible for the regulation of hematopoietic progenitor proliferation, quiescence, or differentiation. More than 30 hematopoietic cytokines and growth factors that increase or decrease progenitor proliferation and differentiation have been cloned and characterized. Although the molecular effect of these factors on hematopoietic cells has been extensively studied, it remains unclear how the combination of these factors regulates the hematopoietic process. In vivo hematopoiesis normally occurs in close proximity with BM stromal elements. Coculture of progenitors with BM stromal feeders in vitro inhibits progenitor proliferation through mechanisms that are as yet not understood.4-6,43,44 Progenitors, as well as cytokines, can bind specifically with ligands on cells and extracellular matrix present in the BM,1-3,45,46 resulting in the colocalization of progenitors at a specific stage of differentiation with a specific array of cytokines.47 This is thought to provide one level of regulation of growth and differentiation. There is also mounting evidence that contact interactions between progenitors and BM stromal ligands may be equally, or even more, important for the regulation of the hematopoietic process. Recent studies have shown that engagement of, for instance, selectins48 and mucins49,50may profoundly affect progenitor survival and growth. Likewise, engagement of integrins may enhance progenitor survival in culture.51 We describe here how integrin engagement alters progenitor growth.

We used 2 experimental assays to investigate these questions. Almost all CD34⁺ cells collected from the PB of individuals treated with G-CSF are in G₀/G₁. In 1 set of studies, we showed that FN coculture of PB CD34⁺cells that are in G₀/G₁ prevents entry into S phase compared with cells cocultured with PLL or BSA, suggesting that engagement of β1-integrins prevents entry into cell cycle. This is consistent with what we have previously shown for steady-state marrow–derived CD34⁺cells4-7 and what we show here for CD34⁺ cells present in cultured (and hence proliferating) mobilized PB CD34⁺ cell populations: when cocultured with FN, but not PLL, the portion of CD34⁺ cells in S phase declines. Using blocking monoclonal antibodies, we showed that induction of G₁/S blockade by adhesion-receptor engagement in human hematopoietic progenitors is β1-integrin specific: in contrast to β1-integrins, engagement of other transmembrane adhesion receptors, such as CD44,7 CD34,7 and CD62L (data shown here), did not affect the proportion of progenitors that is in S phase.

β1-integrin–mediated block in G₁/S transition in hematopoietic cells occurs in late G₁ and is associated with elevated levels of p27^KIP1 and inactivation of cyclin-E/cdk2 complexes. Of interest is the fact that levels of p27^KIP1 were significantly less elevated in uncultured CD34⁺ cells selected fresh from mobilized PB than in CD34⁺ cells cultured for 60 hours with low concentrations of cytokines in contact with FN. This suggests strongly that elevation of p27^KIP1 is not merely a reflection of presence in G₀/G₁ status but is correlated with engagement of integrins.

This is in contrast to what has been described in the majority of other biological systems: engagement of integrins usually activates cyclin-D/cdk4 and cyclin-E/cdk2 or cyclin-A/cdk2 complexes leading to cell proliferation but not growth arrest.13-15,25-27 In contrast to the CD34⁺cells studies here, those reports describe the effect on cell cycle proteins in cells that require adhesion for cell growth, such as fibroblasts, endothelial cells, and myocytes. A few examples have been described of adhesion-mediated G₁-phase arrest mediated through mechanisms similar to what we show here for hematopoietic cells: growth arrest occurred late in G₁ and was due to elevated levels of the “contact” cdki p27 ^KIP1, which inhibits cyclin-E/cdk2 kinase activity.52-55 When α5β1–mediated adhesion of the FET colon carcinoma cell line to FN was prevented, FET cells were induced to proliferate.51 This was associated with activation of extracellular signal-regulated kinase–1 and extracellular signal-regulated kinase–2 and significantly elevated levels of cdk4, phosphorylation of Rb, and increased cyclin-A/cdk2 and cyclin-E/cdk2–associated kinase activity. Thus, as we show here for hematopoietic cells, α5β1 engagement in FET colon carcinoma cells suppresses cyclin-dependent kinase activity, leading to growth arrest. G₁-phase growth arrest was also seen when arterial smooth muscle cells were cultured on polymerized type I collagen.53 This was associated with elevated levels of p27^KIP1 and p21^CIP1 and decreased cyclin-E–associated cdk2 kinase activity. In contrast, when cultured on monomer collagen, arterial smooth muscle cell proliferation was induced rather than growth arrest. Like FN-adherent human CD34⁺ cells, which are round even in the adherent state, arterial smooth muscle cells adherent to polymeric collagen adhere in a rounded state and do not spread. These results suggest that, like lateral association and ligand-binding–site occupation,10 cell shape may be an additional parameter that dictates the type of molecules recruited to focal adhesions and therefore the type of signal pathways that are activated or blocked. This is consistent with recent studies by Chen et al54demonstrating that cell death is influenced not only by integrin engagement by a substrate but also by cell shape.

That cell-cell contact causes normal cells to stop proliferating has long been known in normal organ development. More recently it has become clear that such contact-mediated growth arrest is mediated by up-regulation of the cdki, p27^KIP1,56,57 which inactivates cyclin-E/cdk2 and cyclin-A/cdk2 complexes. This is illustrated in mutant p27 ^KIP1−/− mice that display generalized increased body size and a significantly expanded hematopoietic progenitor pool.56,57 This appears to be consistent with our observation that cell-ECM interaction elevates levels of p27 ^KIP1 and inhibits G₁/S progression of CD34⁺ progenitors. Regulation of p27^KIP1 levels is complex.58 59 Elevated levels can be due to increases in transcription, messenger RNA (mRNA) stabilization, or decreased protein degradation. Preliminary results from ribonucleotide protection assays (results not shown) suggest that the regulation of p27^KIP1 by integrin engagement on CD34⁺ cells may not be at the transcriptional level.

Finally, we found that integrin-mediated block in G₁/S transition can be modulated when external conditions change: addition of supraphysiological concentrations of IL3 and GM-CSF, which bind to a common receptor in the hematopoietic receptor binding family,60 or SCF and Flt-3L, which signal via tyrosine kinase receptors,61 counteracts the adhesion-mediated block in G₁/S progression. Recent studies from other groups have shown that IL3 and SCF activate protein kinase C (PKC) and tyrosine kinases that lead to enhanced adhesive capacity of β1-integrins present on serum- and cytokine-starved CD34⁺ cells and CFC.28-30 In contrast, we show that supraphysiological concentrations of IL3, GM-CSF, SCF, or Flt-3L did not affect adhesion of human CFC or CD34⁺ cells when they were maintained under physiological conditions. Our results are consistent with studies from Strobel et al32 and Schofield et al31 demonstrating that supraphysiological concentrations of cytokines do not alter the adhesive function of integrins under serum/cytokine–replete conditions. Even though adhesion of CD34⁺ cells to FN was not affected by the presence of IL3 or SCF, presence of these supraphysiological concentrations of cytokines prevented adhesion-mediated increased p27^KIP1 levels and prevented adhesion-mediated inhibition of cdk2 activity. Signal pathways activated by cytokine stimulation have been extensively studied. Stimulation of either hematopoietic or tyrosine kinase receptors leads to recruitment and activation of signal and adaptor proteins and to activation of signal pathways that are also recruited/activated by integrin stimulation. Like integrin engagement, stimulation of c-kit leads to phosphorylation of paxillin and CrkL, activation of PI3-kinase, Ras, and MAPK.60,61 Likewise, IL-3 phosphorylates CrkL and paxillin and activates PI3-kinase and MAPK, molecules known to be recruited to and activated in focal adhesions.62-68 Thus, significant overlap exists between signal pathways activated following cell adhesion or stimulation with cytokines. Since the mechanism(s) that underlie adhesion-mediated signaling in hematopoietic cells are unknown, we can only speculate how the combined activation of integrin and cytokine receptors affects hematopoietic cell growth. However, the characterization of conditions that allow adhesion without cell cycle arrest and conditions that induce adhesion with cell cycle arrest should prove useful in deciphering the signal pathways that are activated by engagement of integrins leading to growth arrest of human hematopoietic progenitors.

In conclusion, we demonstrate that cell cycle arrest and reduced proliferation of CD34⁺ cells, which are adherent to FN under physiological cytokine conditions, are mediated by the cdki, p27^KIP1. However, costimulation of FN-adherent progenitors with certain growth-promoting cytokines overrides this integrin-dependent elevation of p27^KIP1 and allows S-phase entry of CD34⁺ cells. Future studies will identify the molecular mechanisms underlying the reversible inhibition of entry in S phase mediated by changes in p27^KIP1.